Beijing GoBroad Boren Hospital

CancerFax acts as your single coordinator for the entire Beijing GoBroad Boren Hospital journey. You begin by sharing your complete haematology records, including bone marrow biopsy and aspirate findings, flow cytometry and cytogenetics, recent imaging, prior chemotherapy, CAR-T or transplant treatment summaries (including the specific CAR-T construct used and response if you have already had CAR-T elsewhere), and minimal residual disease data through our secure intake. Our clinical team reviews your case and identifies whether Beijing GoBroad Boren is the right CAR-T or HSCT centre for your specific diagnosis, taking into account the 30 different CAR-T targets available there. We then submit your case directly to the appropriate clinical lead at the hospital — Director Chunrong Tong for CAR-T research, Dr. Tong Wu for HSCT, Dr. Xiaoyan Ke for lymphoma and myeloma, or other sub-specialty leads.

Once your consultation is confirmed, CancerFax prepares your full pre-travel pack: the hospital's official cost estimate (shared with you without any CancerFax mark-up), Chinese visa documentation, accredited Chinese-English-Russian-Arabic translation of your home-country reports, accommodation guidance in Beijing for the typical 4 to 8 week CAR-T stay or 3 to 6 month HSCT stay, and travel logistics via Beijing's international airports. We remain your single point of contact through admission, CAR-T or HSCT treatment, discharge and post-treatment follow-up. Where useful, we will openly compare Beijing GoBroad Boren alongside parallel pathways at Lu Daopei Hospital (Beijing-Yanda), the Institute of Hematology and Blood Diseases Hospital in Tianjin and Peking University People's Hospital. There is no fee to the patient for any of this coordination.

Both hospitals are part of the GoBroad Healthcare Group, but they are distinct facilities with different roles. Beijing GoBroad Boren Hospital (formerly Beijing Boren Hospital before the GoBroad acquisition) is the group's dedicated hematology-specialty hospital, spanning approximately 14,000 square metres with 19 Level-100 laminar flow wards purpose-designed for hematopoietic stem cell transplantation and post-CAR-T isolation care. This is where the 4,000+ CAR-T clinical research cases have been performed since 2017, and where Director Chunrong Tong's CAR-T research programme is based. Beijing GoBroad Hospital, by contrast, is the group's larger flagship research-oriented general hospital completed in July 2023 in Beijing's Changping ZhongGuanCun Life Science Park, spanning approximately 100,000 square metres with a broader scope covering solid tumours, hematologic malignancies and neuroscience plus Lu-177 radionuclide therapy. For pure CAR-T and HSCT cases, the Boren campus is typically the right destination. For complex multidisciplinary solid tumour cases or Lu-177-eligible neuroendocrine tumours, the Changping flagship may be more appropriate. CancerFax confirms which campus is right for your case before any travel.

Beijing GoBroad Boren Hospital offers an unusually broad CAR-T platform with 30 different CAR-T targets, one of the widest of any single centre worldwide. The major categories include: B-cell malignancy CAR-T (CD19 single-target, CD22 single-target, CD20 single-target and CD19/CD22/CD20 triple-target constructs) for B-ALL and B-cell lymphoma; T-cell malignancy CAR-T (CD7 CAR-T and CD5 CAR-T) for refractory T-cell ALL and T-cell lymphoma — both rare and clinically important constructs that very few centres globally offer at scale; multiple myeloma CAR-T (BCMA-targeting); CAR-NK cell therapy programmes; and universal CAR-T (UCAR-T) 'off-the-shelf' allogeneic CAR-T platforms. The hospital also pioneered sequential CAR-T strategies (CD19 CAR-T followed by CD22 CAR-T) for B-ALL patients who relapse after the first CAR-T treatment, with a published five-year follow-up study in the international haematology journal Haematologica. CancerFax assesses which specific CAR-T target is most appropriate for your case based on your disease subtype, prior treatment history and CAR-T relapse mechanism if any.

Yes. Beijing GoBroad Boren Hospital actively accepts foreign-language medical records (in English, Russian, Arabic and Chinese) and provides written opinions before any travel commitment, particularly for haematology cases where the entire CAR-T or HSCT eligibility assessment can largely be made from records alone — bone marrow biopsy and aspirate findings, flow cytometry, cytogenetics, prior treatment history (including any prior CAR-T construct used and disease response), and donor availability for HSCT candidates. CancerFax facilitates the submission, coordinates accredited translation of your reports, follows up on your behalf and helps you understand the resulting opinion, including how it compares with treatment plans from Lu Daopei Hospital, IHBDH Tianjin and Peking University People's Hospital. A remote opinion is the most efficient first step for complex CAR-T or HSCT cases.

As a Chinese hematology-specialty hospital, Beijing GoBroad Boren Hospital offers CAR-T cell therapy at substantially lower cost than equivalent FDA-approved commercial CAR-T (such as Yescarta, Kymriah, Tecartus, Breyanzi, Carvykti or Abecma) in the United States or Western Europe. Chinese investigational CAR-T constructs at high-volume Chinese centres typically range from US$50,000 to US$150,000 inclusive of CAR-T product and inpatient stay, compared with US$400,000 or more for the CAR-T product alone in the United States. Costs are broadly comparable with Lu Daopei Hospital (the other major Chinese CAR-T centre CancerFax works with closely), though specific pricing depends on the CAR-T target chosen, whether bridging to allogeneic HSCT is required, and complication contingency. CancerFax shares Beijing GoBroad Boren's official cost estimates with you at no extra charge and without any CancerFax mark-up, and we are happy to compare them openly with Lu Daopei, IHBDH and international CAR-T centres before any decision is made. We always recommend asking for a 'complication contingency' estimate alongside the base CAR-T cost, because cytokine release syndrome and infection management can add meaningfully to the total.